Standout Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial... 2024 202637
  1. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial (2024)
    Qiao Li, Qingyuan Zhang et al. Nature Communications

Immediate Impact

55 standout
Sub-graph 1 of 23

Citing Papers

Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout

Works of Qiao Li being referenced

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
2021

Author Peers

Author Last Decade Papers Cites
Qiao Li 929 518 756 644 147 2.0k
Jianxin Xue 766 744 415 767 135 2.2k
F. William Orr 1221 436 766 1184 77 2.9k
Qingyuan Zhang 1333 605 760 1252 134 2.9k
Yasuo Hozumi 944 511 686 321 84 1.9k
Toru Kumagai 1381 1356 733 1042 154 3.1k
Carmine Carbone 892 372 525 1132 83 2.3k
Shuang Liu 519 259 613 1087 125 2.2k
Riccardo Giampieri 1237 684 578 680 121 2.2k
Ling Xu 487 227 1100 1138 127 2.2k
Daniel G. Stover 1413 635 750 1234 143 2.9k

All Works

Loading papers...

Rankless by CCL
2026